Mankind Pharma's Rs 10,000 crore debt bet on Bharat Serums: Masterstroke or risky gamble?

Mankind Pharma, India's fourth-largest pharmaceutical company, is going all in on its latest acquisition. Historically known for its debt-free status, the pharma giant is going to raise Rs 10,000 crore through non-convertible debentures and commercial paper to fund its Rs 13,630 crore acquisition of Bharat Serums & Vaccines (BSV). In addition, it may dilute equity and raise another Rs 3,000 crore through a Qualified Institutional Placement (QIP). With the total funds being raised greater than the existing balance sheet size, the stakes are not just high—they are unprecedented. So, is the risk worth it? To determine that, we must consider three key questions that serve as a litmus test for any acquisition. Q1: Does the acquisition provide new growth opportunities? The answer appears to be yes. BSV specialises in women's h